Table 2.
In vivo NKG2D ligand expression in sequential Ewing sarcoma tumour samples
| UPNa | sample type (years after diagnosis) | MICA | ULBP1 |
|---|---|---|---|
| 1 | post-chemotherapy resection-GRb | n.e. | + |
| lung metastasis (2) | ++ | + | |
| mediastinal metastasis (3) | ++ | + | |
| 2 | pre-treatment biopsy | ++ | + |
| post-chemotherapy resection-GR | + | ++ | |
| lung metastasis (5) | + | +/- | |
| lymph node metastasis (9) | ++ | n.e. | |
| 3 | pre-treatment biopsy | + | + |
| post-chemotherapy resection-GR | ++ | + | |
| lung metastasis (3) | + | ++ | |
| lung metastasis (4) | + | n.e. | |
| 4 | pre-treatment biopsy | + | + |
| post-chemotherapy resection-PRc | ++ | + | |
| bone metastasis (1) | ++ | - | |
| 5 | pre-treatment biopsy | ++ | +/- |
| post-chemotherapy resection-PR | ++ | + | |
| lung metastasis (1) | ++ | +/- | |
| 6 | pre-treatment biopsy | ++ | - |
| post-chemotherapy resection-PR | ++ | +/- | |
| lung metastasis (0.5) | ++ | - | |
| lung metastasis (2.5) | ++ | +/- | |
| lung metastasis (3) | ++ | +/- | |
| bone metastasis (3) | ++ | - | |
| 7 | post-chemotherapy resection-PR | ++ | +/- |
| lung metastasis (1.5) | ++ | + | |
| bone metastasis (2.5) | ++ | +/- | |
| lung metastasis (4) | ++ | + | |
| lung metastasis (4) | ++ | +/- | |
| lung metastasis (5) | ++ | ++ | |
| paravertebral metastasis (5) | ++ | + | |
| 8 | pre-treatment biopsy | ++ | + |
| post-chemotherapy resection-GR | + | n.e. | |
| lung metastasis (8) | ++ | + | |
aUPN = unique patient number. bGR = good chemotherapy response. cPR = poor chemotherapy
response. n.e. = not evaluable.-= absent, +/- = weak, + = moderate, ++ = strong expression.